Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - … journal of chronic …, 2014 - Taylor & Francis
Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
[HTML][HTML] Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
W Vincken, J Aumann, H Chen, M Henley… - … Journal of Chronic …, 2014 - europepmc.org
Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley, D McBryan… - 2014 - pubmed.ncbi.nlm.nih.gov
Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - … Journal of Chronic …, 2014 - dovepress.com
Background: Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
[HTML][HTML] Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - … Journal of Chronic …, 2014 - ncbi.nlm.nih.gov
Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
W Vincken, J Aumann, H Chen… - Int J Chron Obstruct …, 2014 - researchportal.vub.be
BACKGROUND: Addition of a second bronchodilator from a different pharmacological class
may benefit patients with moderate-to-severe chronic obstructive pulmonary disease …
may benefit patients with moderate-to-severe chronic obstructive pulmonary disease …
[引用][C] Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - International Journal of …, 2014 - cir.nii.ac.jp
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus
indacaterol alone in COPD patients: the GLOW6 study | CiNii Research CiNii 国立情報学 …
indacaterol alone in COPD patients: the GLOW6 study | CiNii Research CiNii 国立情報学 …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - International Journal of …, 2014 - go.gale.com
Background: Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
W Vincken, J Aumann, H Chen, M Henley… - … Journal of Chronic …, 2014 - dovepress.com
Background: Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
W Vincken, J Aumann, H Chen, M Henley… - … Journal of Chronic …, 2014 - europepmc.org
Background Addition of a second bronchodilator from a different pharmacological class may
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …
benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) …